Torsdag 15 Maj | 01:02:41 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-10 07:30 Kvartalsrapport 2025-Q2
2025-06-26 N/A Årsstämma
2025-05-23 N/A X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.
2023-02-08 08:00:00

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed a distribution partnership for ASTar Instrument and consumables for the UK market with Pro-Lab Diagnostics.

Q-linea’s updated marketing strategy includes, among other things, collaborations to achieve a broader reach for ASTar via distribution partnerships. Q-linea has signed a distribution agreement for the UK market with Pro-Lab Diagnostics as sole distribution partner, however, Q-linea also has the right to address this market. The agreement is based on a transfer price model with yearly performance targets to be assessed by Q-linea.
 
“Antimicrobial resistance continues to present a challenge to the diagnostics industry and its rapid and accurate management is of paramount importance. We are delighted to partner with Q-linea in the UK and look forward to introducing this exciting technology into the fight against sepsis,” said Mark Reed, General Manager of Pro-Lab Diagnostics.
 
"I am really pleased that we are taking the first step in our updated commersialisation strategy with Pro-Lab Diagnostics. We have known them for several years and their deep expert knowledge in the microbiology space is truly impressive. The UK market is one of our priorities for 2023, both regarding size and the interest we have seen so far and because it is a leading region when it comes to sepsis awareness. I look forward to seeing how we together can approach the UK market and I expect to see traction during 2023," said Jonas Jarvius, CEO of Q-linea.

About Pro-Lab Diagnostics
Pro-Lab Diagnostics is based in Canada, but also has operation in the US and UK. The company was formed in Canada in 1974 and the UK subsidiary was formed in 1989. The team is around 100 people and has a deep understanding and history in the microbiology market.
 
About ASTar Instruments and ASTar BC G-Kit 
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
 
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.